The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The
https://
ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
the contents by NLM or the National Institutes of Health.
Learn more:
PMC Disclaimer
浙江大学医学院附属第一医院血液科，浙江省血液肿瘤（诊治）重点实验室，浙江大学癌症中心，浙江省血液病临床医学研究中心，杭州 310003,
Department of Hematology, the First Affiliated Hospital of Zhejiang University, College of Medicine; Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment; Cancer Center of Zhejiang University; Zhejiang Provincial Clinical Research Center For Hematologic Diseases, Hangzhou 310003, China
https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208573s000lbl.pdf
.
15.
Mei M, Aldoss I, Marcucci G, et al. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use[J]
Am J Hematol.
2019;
94
(3):358–362. doi: 10.1002/ajh.25369.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
16.
Wang ES, Baron J. Management of toxicities associated with targeted therapies for acute myeloid leukemia: when to push through and when to stop[J]
Hematology Am Soc Hematol Educ Program.
2020;
2020
(1):57–66. doi: 10.1182/hematology.2020000089.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
17.
Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study[J]
Lancet Oncol.
2017;
18
(8):1061–1075. doi: 10.1016/S1470-2045(17)30416-3.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
18.
Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML[J]
N Engl J Med.
2019;
381
(18):1728–1740. doi: 10.1056/NEJMoa1902688.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
19.
Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J]
Blood.
2017;
130
(6):722–731. doi: 10.1182/blood-2017-04-779405.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
20.
DiNardo CD, Stein EM, de Botton S, et al. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML[J]
N Engl J Med.
2018;
378
(25):2386–2398. doi: 10.1056/NEJMoa1716984.
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
21.
DiNardo CD, Stein AS, Stein EM, et al. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia[J]
J Clin Oncol.
2021;
39
(1):57–65. doi: 10.1200/JCO.20.01632.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
22.
Cortes JE, Heidel FH, Hellmann A, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome[J]
Leukemia.
2019;
33
(2):379–389. doi: 10.1038/s41375-018-0312-9.
[
PMC free article
]
[
PubMed
] [
CrossRef
]
[
Google Scholar
]
23.
Sallman DA, Asch AS, Kambhampati S, et al. The First-in-Class Anti-CD47 Antibody Magrolimab Combined with Azacitidine Is Well-Tolerated and Effective in AML Patients: Phase 1b Results[J]
Blood (ASH Annual Meeting Abstract)
2020:#330.
[
Google Scholar
]
Articles from
Chinese Journal of Hematology
are provided here courtesy of
Editorial Office of Chinese Journal of Hematology
